BC Extra | Jun 18, 2019
Company News

BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination...
BC Week In Review | Oct 19, 2018
Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
BC Extra | Oct 16, 2018
Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
BC Innovations | Aug 1, 2018
Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
BC Week In Review | Jul 20, 2018
Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an...
BC Extra | Jul 18, 2018
Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an...
BioCentury | Jun 12, 2018
Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...
BC Innovations | Jul 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF -dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five...
BC Week In Review | Feb 10, 2017
Company News

Q BioMed, Oklahoma Medical Research Foundation, RGCB deal

Q BioMed partnered with the non-profit Oklahoma Medical Research Foundation and the Indian government-owned RGCB to develop uttroside B, a preclinical chemotherapeutic, and its derivatives to treat hepatocellular carcinoma (HCC). The biotech cited an animal...
BC Innovations | Nov 30, 2016
Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse studies suggest dual inhibition of MAP2K1 / MAP2K2 or MAPK1 / MAPK3 could help treat PTEN hamartoma tumor syndrome (PHTS), a type of skin hyperplasia that can become malignant. In a...
Items per page:
1 - 10 of 18